RBS Upgrades AstraZeneca (AZN) to Buy
AZN Hot Sheet
Rating Summary:2 Buy, 6 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 7 | New: 18
RBS upgrades AstraZeneca (NYSE: AZN) from Hold to Buy.
To see more analyst ratings on AZN Click Here.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
To see more analyst ratings on AZN Click Here.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
You May Also Be Interested In
- Basilea participates in public-private collaboration to tackle antibiotic resistance
- UPDATE: Nomura Securities Upgrades Central European Distribution (CEDC) to Neutral; Strategic Alliance with Russian Standard
- Deutsche Bank Upgrades Siemens (SI) to Buy; Subtle Shift
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
